Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anthony Amabile

Internal Medicine Virginia Beach, VA Medical Doctor

NPI 1669445078 CMS profile 347456

816 Independence Blvd, Suite 1H, Virginia Beach, VA 23455

Open in the dashboard

General payments

$8,540

520 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anthony Amabile of Virginia Beach, VA is reported in the CMS Open Payments database as having received $8,540 across 520 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,576 92
2024 General $1,201 61
2023 General $630 30
2022 General $668 39
2021 General $549 27
2020 General $1,129 71
2019 General $2,786 200

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Amabile
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Anthony Amabile were reported at $1,576. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Anthony Amabile Internal Medicine median Middle half National median
2019 $2,786 $159 $48–$570 $163
2020 $1,129 $119 $33–$402 $114
2021 $549 $135 $37–$521 $132
2022 $668 $141 $42–$496 $149
2023 $630 $149 $45–$519 $160
2024 $1,201 $154 $47–$537 $164
2025 $1,576 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,838 103 payments
  2. Novo Nordisk Inc $966 65 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $932 59 payments
  4. Amgen Inc. $923 54 payments
  5. Lilly USA, LLC $547 37 payments
  6. Pfizer Inc. $463 30 payments
  7. Novartis Pharmaceuticals Corporation $428 25 payments
  8. Sanofi-Aventis U.S. LLC $278 20 payments
  9. Janssen Pharmaceuticals, Inc $237 19 payments
  10. AbbVie, Inc. $219 12 payments
  11. Other $1,710 96 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,529 518 payments
  2. Education $11 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $1,305 68 payments
  2. Ozempic $801 55 payments
  3. Repatha $632 31 payments
  4. RYBELSUS $575 38 payments
  5. JARDIANCE Diabetes $369 27 payments
  6. JARDIANCE Diabetes $336 17 payments
  7. Otezla $313 20 payments
  8. SYMBICORT $301 16 payments
  9. JARDIANCE Diabetes $275 20 payments
  10. XARELTO $269 21 payments
  11. Other $6,550 410 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 115 drugs

Part D claims

7,005

Median for Internal Medicine: 777

Drug cost

$1,092,172

Median for Internal Medicine: $73,373

Branded share of claims

24.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 173 $293,830
Jardiance Empagliflozin Brand 87 $123,160
Eliquis Apixaban Brand 131 $117,996
Farxiga Dapagliflozin Propanediol Brand 106 $110,800
Repatha Sureclick Evolocumab Brand 42 $52,570
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 41 $37,660
Trulicity Dulaglutide Brand 19 $33,237
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 33 $33,073
Januvia Sitagliptin Phosphate Brand 18 $28,000
Entresto Sacubitril/Valsartan Brand 27 $27,593

The 10 drugs with the highest cost, of 115 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$296,144

Of which drugs: $56,484

Medicare patients

601

Average age 75

Services billed

7,025

312 women, 289 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 38%
Diabetes 29%
Ischemic heart disease 28%
Osteoporosis 28%
Cancer 20%
COPD 19%
Depression 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 26 2,042 $41,367
Pcv20 vaccine im 90677 Office 30 30 $8,105
Vaccine for influenza for injection into muscle 90662 Office 83 83 $6,722

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $194
  • Lilly USA, LLC $28
$223 87 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $89
$89 106 —
Repatha
  • Amgen Inc. $77
$77 69 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $74
$74 33 —
MOUNJARO
  • Lilly USA, LLC $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

520 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record